|
Title
|
|
|
|
An in-depth evaluation of the validity and logistics surrounding the testing of AR-V7 mRNA expression in circulating tumor cells
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Recent reports have emphasized the clinical relevance of detecting the androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs). Our aim was to set up a validated multicenter pipeline to measure AR-V7 by RT-qPCR in RNA isolated from CellSearch-enriched CTCs to provide an AR-V7 positive/negative score in a clinically acceptable time range. CellSearch-enirched CTCs from metastatic castration-resistant prostate cancer patients were characterized by RT-qPCR. After optimization it was prospectively tested whether it was possible to report the AR-V7 status within 11 days (PRELUDE study). In the range of the RNA equivalent of 0.2 to 12 VCaP cells the coefficient of variation for AR-V7 was 9% (n = 37). The LOD was 0.3 and the LOQ 3 cells in the final RT-qPCR. No differences were observed between AR-V7 data generated by four technicians or in two different laboratories. For the 45 patients in the PRELUDE study, 13 patients were ineligible, 22 patients were AR-V7 negative, and 10 AR-V7 positive. The median time to inform the physician of the test result was 7 (2 to 11) days. THIS assay CAN establish the AR-V7 status in CTCs from metastatic castration-resistant prostate cancer patients. Furthermore, it was possible to provide an AR-V7 outcome within 11 days, indicating that it may be used to choose between an anti-AR or taxane-based cabazitaxel treatment. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
The journal of molecular diagnostics / American Society for Investigative Pathology; Association for Molecular Pathology [Bethesda, Md] - Bethesda, Md
| |
|
Publication
|
|
|
|
Bethesda, Md
:
2018
| |
|
ISSN
|
|
|
|
1525-1578
| |
|
DOI
|
|
|
|
10.1016/J.JMOLDX.2018.01.008
| |
|
Volume/pages
|
|
|
|
20
:3
(2018)
, p. 316-325
| |
|
ISI
|
|
|
|
000431095900007
| |
|
Pubmed ID
|
|
|
|
29474983
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|